Gene-Editing Platform Makes it Easier to Create HIV-Resistant Immune Cells
Researchers at UC San Francisco and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection.
The team built a high-throughput cell-editing platform using a variant of CRISPR/Cas9 technology that allowed them to test how well scores of different genetic tweaks defended immune cells against HIV. The new system allows researchers to quickly modify the genetic code of freshly donated human immune cells and will hopefully accelerate the quest to finally cure HIV+ patients, the researchers said.
“This is an ability HIV researchers have wanted for a long time,” said postdoctoral researcher Judd F. Hultquist, PhD, one of the new paper’s co-lead authors. “I hope this will take what seemed like an insurmountable task a year ago and make it something everyone can do.”
The research, which was published online Oct. 25, 2016, in Cell Reports, was conducted by the laboratories of co-senior authors Nevan J. Krogan, PhD, a professor of cellular and molecular pharmacology at UCSF, director of the Quantitative Biosciences Institute (QBI) in UCSF’s School of Pharmacy, and a senior investigator at the Gladstone Institutes, and Alexander Marson, MD, PhD, an assistant professor of microbiology and immunology in the UCSF School of Medicine. The research was spearheaded by Hultquist, who is in Krogan’s lab, and Kathrin Schumann, PhD, a postdoctoral researcher in Marson’s lab.
Gene Editing Offers Possibility of HIV Cure
Despite great progress made since the 1980s in the ability to treat and control HIV with antiretroviral drugs, there is still no cure for the virus, and millions of people are newly infected every year. Once the virus infiltrates a patient’s immune system, it can hide indefinitely within cells’ own DNA, impossible to detect or destroy with current technology. As a result, patients must continue on antiretroviral drugs for the rest of their lives.
However, not everyone is susceptible to the virus. Scientists have taken inspiration from a group of individuals whose immune cells appear to be naturally resistant to HIV infection, and hope to one day edit HIV patients’ immune systems to mimic the biology of these HIV-resistant individuals.
“There have been lots of efforts to sequence the genomes of resistant people to discover the mutations that make them immune to the virus,” Hultquist said. “But there are many different genes that could be involved: some control the virus’s ability to enter immune cells, others control how the virus tricks cells into expressing its genes. Until now, there was no way to test which of these mutations actually confer resistance in primary human T-cells.”
CRISPR-Based Platform Aims to Accelerate Search for Cures
Despite being the immune system’s lead fighters, T cells are delicate – only able to survive outside the body for a couple weeks. They are also resistant to the viruses researchers use in other cell types to deliver DNA instructions about how to build the machinery needed for CRISPR/Cas9 gene editing. Last year, Marson and Schumann successfully used CRISPR to perform precise DNA sequence replacements in primary human T cells for the first time by prefabricating the CRISPR machinery in test tubes, then adding it to the freshly donated immune cells.
“It’s incredibly fast,” Schumann said. “The desired editing occurs rapidly, and then the cell degrades the CRISPR machinery so it can’t go on making changes. That’s really important: otherwise it’s like doing surgery and leaving in the scalpel.”
In the new paper, Schumann and Hultquist improved the technique by devising an automated system for high-throughput, parallel editing of T cells. The new approach enables the researchers to mutate different candidate genes in hundreds of thousands of T cells from healthy volunteers, expose these mutant cells to the HIV virus, then screen through the cells to find which mutations were able to prevent infection.
A key feature of this system is its speed, as donated T cells can only survive outside of the body for two to three weeks. “If we want to start editing T cells and putting them back into people as a therapy,” Krogan said, “I think this will be the gold standard for how to do that quickly, safely, and efficiently.”
The researchers used the new technique to mutate the genes CXCR4 and CCR5, which encode receptor molecules that different strains of the HIV virus use to sneak in and infect immune cells and which have been targeted in previous cell therapy trials. Inactivating either of these genes successfully blocked HIV infection of the human T cells by the relevant HIV strain.
Additional experiments showed the feasibility of creating a two-layer security system for T cells by simultaneously blocking a gene the HIV virus needs to gain entry into cells and a gene the virus needs to survive and reproduce within the cell, resulting in doubly secure resistance.
To demonstrate the efficiency and power of the new high-throughput technology, the researchers also developed 146 different CRISPR-based edits, each designed to deactivate one of 45 genes linked to HIV’s ability to integrate into host cells. They identified several genes whose absence conferred HIV resistance, some of which had been predicted by previous studies and others that had never been directly tied to HIV infection before.
‘Tip of the Iceberg’ for Infectious Disease Research
The researchers plan to use the new platform to identify additional weaknesses in the HIV virus’s life cycle that could be exploited either by cell therapy or targeted drugs. They also want to be able to insert more subtle mutations, such as those reported in HIV-resistant individuals, which could alter cell function just enough to confer resistance but without fully deactivating the gene and impeding cell function.
However, their greater hope is that the system will have much broader applications than just HIV and eventually be used in labs around the world to study the virus of their choice.
“This toolkit has been a huge missing piece in infectious disease research,” Marson said. “Now we have the ability to make modifications in human immune cells and right away see the effects. The potential is immense — this is just the tip of the iceberg.”
Additional authors on the new paper include Jonathan M. Woo, MS, of UCSF; Michael J. McGregor, MS, of UCSF and the Gladstone Institutes; Lara Manganaro, PhD, and Viviana Simon, MD, PhD, of Mt. Sinai Icahn School of Medicine; and Jennifer Doudna, PhD, of UC Berkeley, the Howard Hughes Medical Institute and Adjunct Professor of Cellular and Molecular Pharmacology at UCSF. Krogan is director of the UCSF site of the California Institute for Quantitative Biosciences (QB3). Marson is a member of the Divisions of Infectious Diseases and Rheumatology in the UCSF Department of Medicine, the UCSF Diabetes Center, and the Helen Diller Family Comprehensive Cancer Center. Marson and Doudna are members of the University of California Innovative Genomics Initiative.
This research was supported by UCSF; the National Institutes of Health, National Institute of Allergy and Infectious Disease, and National Institute of General Medical Sciences (R01 AI064001, P50 GM082250, U19 AI106754, P01 AI090935, CFAR, and P30 AI027763); the Deutsche Forschungsgemeinschaft (SCHU3020/2-1); the UCSF Sandler Fellowship; and a gift from Jake Aronov.
Marson has filed a patent on the use of Cas9 RNPs to edit the genome of human primary T cells, and serves as an advisor to Juno Therapeutics independently from this work.
About UCSF: UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland – and other partner and affiliated hospitals and healthcare providers throughout the Bay Area. Please visit www.ucsf.edu/news.
About the Gladstone Institutes: To ensure our work does the greatest good, the Gladstone Institutes focuses on conditions with profound medical, economic, and social impact—unsolved diseases of the brain, the heart, and the immune system. Affiliated with the University of California, San Francisco, Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease.